LYRA Stock Jumps After Breakthrough Sinus Implant Trial Results | ENLIGHTEN-2 Update<br />http://newsplusglobe.com/<br />ItLyra Therapeutics (NASDAQ: LYRA) just announced major success from its Phase 3 ENLIGHTEN-2 clinical trial for LYR-210, a long-acting sinus implant treating chronic rhinosinusitis (CRS). The treatment significantly improved all three key CRS symptoms over 24 weeks, with statistical strength and solid safety results.<br /><br />In this video, we break down what the data means, how the market reacted, and what could be next for LYRA investors—including the potential road to FDA approval.<br /><br />📈 Trial Highlights:<br />– Improved nasal obstruction, discharge & facial pain (p=0.0078)<br />– Strong SNOT-22 score gains (p=0.0101)<br />– Results visible by Week 4 and sustained to Week 24<br />– Positive safety profile similar to placebo<br /><br />Is LYRA stock a biotech sleeper hit? Watch now and subscribe for more clinical trial stock coverage!<br /><br />#LyraTherapeutics #LYRAstock #BiotechNews #ENLIGHTEN2 #FDAapproval #ChronicRhinosinusitis #MedicalStocks #StockMarketNews #fyp #newsplusglobe
